13th edition

Format
HYBRID

December 3rd & 4th, 2024

IN-PERSON | LILLE, FR

December 11th& 12th 2024

ONLINE MEETINGS

Navigating a deal structure: Overview, market practices and how to approach

Edition

Navigating a deal structure: Overview, market practices and how to approach

Discussing the landscape of deal structures in the biotech industry, experts will provide their experience in deal-making and asset-licensing. What are the different deal structures? Has there been any innovative and less conventional deal structure types in the past few years for licensing early-stage assets to big pharma? How do deal structures vary based on the area of technology or therapeutic indication, and what factors influence their adoption? What considerations should biotech or TTOs take into account when exploring deal structures with pharma? How will Pharma select potential assets in the future? What are the key points of a successful deal? What best practices can we learn from the recent years and what advice can the experts offer to the newcomers in the sector?

Moderator: Chris Shelley, Partner – IP, IT & Commercial, Penningtons Manches Cooper LLP

Guy Hélin

CEO
Belgium
Syngulon

Lilian Alcaraz

VP, Early Innovation Partnering EMEA
United Kingdom
Johnson & Johnson Innovation

Lubor Gaal

Chief Financial Officer
Norway
Circio Holding ASA

Tamar Raz

CEO
Israel
Hadasit
Scroll to Top
  • No products in the cart.